At the Myeloma 2015 meeting, Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) provides an overview of potential new immune-based approaches for the treatment of multiple myeloma. Studies of antibodies, checkpoint inhibitors and immunomodulatory drugs are currently in evaluation in multiple clinical trials. Combination approaches are receiving interest too.
